Feighner Jp
About
In The Last Decade
Feighner Jp
16 papers receiving 404 citations
Peers
Comparison fields: 5 of 62
- Pharmacology 282
- Psychiatry and Mental health 214
- Experimental and Cognitive Psychology 141
- Cellular and Molecular Neuroscience 74
- Cognitive Neuroscience 49
Countries citing papers authored by Feighner Jp
This map shows the geographic impact of Feighner Jp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feighner Jp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feighner Jp more than expected).
Fields of papers citing papers by Feighner Jp
This network shows the impact of papers produced by Feighner Jp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feighner Jp. The network helps show where Feighner Jp may publish in the future.
Co-authorship network of co-authors of Feighner Jp
This figure shows the co-authorship network connecting the top 25 collaborators of Feighner Jp. A scholar is included among the top collaborators of Feighner Jp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feighner Jp. Feighner Jp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | [Clinical effects of serotonin reuptake inhibitors--a review]. | 2 |
| 2 | The role of venlafaxine in rational antidepressant therapy. | 51 |
| 3 | Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. | 74 |
| 4 | A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. | 51 |
| 5 | A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. | 57 |
| 6 | Pilot study of alpidem, a novel imidazopyridine compound, in anxiety. | 5 |
| 7 | Buspirone in the long-term treatment of generalized anxiety disorder. | 55 |
| 8 | A review of controlled studies of adinazolam mesylate in patients with major depressive disorder. | 8 |
| 9 | [Review of studies of trazodone at the Feighner Research Institute in ambulatory and hospitalized patients]. | 1 |
| 10 | A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. | 58 |
| 11 | A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients. | 24 |
| 12 | Open label study of alprazolam in severely depressed inpatients. | 11 |
| 13 | Long-term therapy for depression with trazodone. | 19 |
| 14 | The use of bupropion in hospitalized depressed patients. | 17 |
| 15 | Benzodiazepines as antidepressants. A triazolobenzodiazepine used to treat depression. | 8 |
| 16 | [Diagnosis criteria from the Saint Louis school (Missouri-USA)]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.